ABSTRACT
The use of laparoscopic sacral colpopexy (LSC) to treat pelvic organ prolapse has increased in recent years coinciding with a dramatic decline in transvaginal mesh use as a result of recent food and drug administration warnings [1]. In the united states, the number of LSC procedures performed for prolapse exponentially increased during the 10 years from 2003 to 2012 [2]. Among urologists in the united states, in 2012, 70.1% of sacral colpopexies were performed by laparoscopy.
